Beyond 'Less Bad': New Push for True TRD Remission

The Shifting Standard of Care for Treatment-Resistant Depression

A growing chorus of psychiatrists is pushing back against the long-accepted practice of declaring partial symptom relief a treatment success. In a recently published discussion in Psychiatric Times, leading clinicians argued that settling for "less bad" outcomes in treatment-resistant depression (TRD) is no longer clinically or ethically defensible. Instead, they are calling for aggressive, individualized care strategies explicitly aimed at achieving full remission — not just a reduction in how bad things are.

This represents a meaningful inflection point in how the psychiatric community is framing TRD management. For the estimated 30% of people with major depressive disorder who do not respond adequately to two or more antidepressant trials, the stakes of this debate are deeply personal. The Psychiatric Times discussion underscores that treatment pathways must be dynamic, patient-centered, and willing to incorporate emerging interventions — particularly when standard pharmacotherapy has already failed.

What the Clinical Discussion Actually Said

The core tension explored by these clinicians is a familiar one in psychiatry: how aggressively should providers pursue remission versus managing tolerability and quality of life? For too long, the field defaulted to stabilization — getting patients to a functional baseline — without necessarily targeting the full resolution of depressive symptoms. The clinicians in this discussion argue that approach does patients a disservice.

Several key themes emerged from the conversation. First, remission should be the explicit goal, not response. A patient who moves from severe to moderate depression has responded, but has not remitted. The difference matters enormously for long-term outcomes, relapse risk, and quality of life. Second, side effect burden must be weighed against the cost of under-treatment. Tolerability concerns are real, but they should not become a reason to stop optimizing care. Third, patient priorities must anchor the treatment plan — what remission looks like for a 28-year-old returning to work differs from what it means for a 65-year-old managing chronic pain alongside depression.

The discussion also acknowledged the widening menu of options now available for TRD, including augmentation strategies, neuromodulation therapies like TMS and ECT, and rapid-acting interventions. This is precisely where the conversation intersects directly with ketamine-assisted treatment.

Where Ketamine Therapy Fits in the Remission-First Framework

At Ketamine Clinics Online, this remission-first framing resonates deeply with the clinical philosophy behind ketamine-assisted treatment. Ketamine — particularly IV ketamine and FDA-approved esketamine (Spravato) — was developed precisely because a significant portion of patients with TRD were being left behind by conventional pharmacotherapy. The rapid-acting mechanism of ketamine, which works on NMDA glutamate receptors rather than the monoamine system targeted by traditional antidepressants, offers something qualitatively different: relief that can begin within hours, not weeks.

The Psychiatric Times discussion reinforces that for patients who have exhausted first- and second-line treatments, waiting months to titrate another antidepressant — while continuing to suffer — is an outcome the field should no longer accept. Ketamine therapy is not a last resort for the desperate; it is an evidence-supported, guideline-recognized intervention that belongs earlier in the TRD conversation, especially when rapid symptom relief is a clinical priority.

It's also worth noting that the individualization emphasis in this discussion aligns with how ketamine treatment is delivered. Dosing, frequency, route of administration, and adjunctive psychotherapy are all variables that can and should be tailored to the patient's specific symptom profile, history, and goals. This is not a one-size-fits-all treatment — and the psychiatric community's move toward personalized TRD management only strengthens the case for including it in the toolkit.

What This Means for Patients and Providers in 2026

The practical implications of this shift are significant. For patients currently in treatment: if your provider has not discussed your remission goals explicitly — not just your symptom scores — that is a conversation worth initiating. For providers: the field is signaling that a patient who remains significantly symptomatic after multiple medication trials deserves an active, escalating plan, not a waiting room.

For those exploring ketamine therapy specifically, this clinical momentum is encouraging. As psychiatry formally raises the bar from "tolerable" to "recovered," interventions that can reliably move treatment-resistant patients toward remission will continue to gain traction. The evidence base for ketamine in TRD has grown substantially over the past decade, and the 2026 clinical conversation is catching up to what many patients and clinicians have already experienced firsthand.

The bottom line: depression treatment in 2026 should not stop when things get slightly better. The goal is full recovery — and for patients who haven't found it yet, options like ketamine therapy exist specifically to help get there.